1 Department of Cellular and Molecular Physiology, School of Medicine, Yale University, New Haven, Connecticut 06520; 2 Department of Physiology, University of Tübingen, 72076 Tübingen, Germany; and 3 Division of Biochemistry and Molecular Biology, Australian National University, Canberra, ACT 0200, Australia
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Heterodimeric amino acid transporters are comprised of two
subunits, a polytopic membrane protein (light chain) and an associated type II membrane protein (heavy chain). The heavy chain rbAT (related to b0,+ amino acid transporter) associates with the light
chain b0,+AT (b0,+ amino acid transporter) to
form the amino acid transport system b0,+, whereas the
homologous heavy chain 4F2hc interacts with several light chains to
form system L (with LAT1 and LAT2), system y+L (with
y+LAT1 and y+LAT2), system x
heavy and light chains; disulfide bridge; cystinuria; lysinuric protein intolerance
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
AMINO ACID TRANSPORTERS ACCOMPLISH in parallel with peptide transporters the uptake of amino acids from food in the small intestine, the release into blood, and subsequent uptake of amino acids from the blood into tissues such as liver or skeletal muscle or the reabsorption of amino acids from the urine along the kidney nephron. In the central nervous system, amino acid transporters regulate the transport of amino acids across the blood-brain barrier or are involved in the reuptake of neurotransmitter amino acids such as glycine, aspartate, or glutamate from the synaptic cleft and are important for the metabolic coupling of astrocytes and neurons. In the placenta, amino acid transporters supply the fetal blood with nutrients from the maternal side and help detoxify the fetal blood. Other amino acid transporters are involved in basic cellular functions such as cell volume regulation, the synthesis of glutathione (GSH), the provision of amino acids for protein synthesis, and energy metabolism.
According to their specialized functions, amino acid transporters fall into different families that are distinguished by the functional properties (specificity of amino acids transported, transport mechanism, coupling to ions) and their molecular similarity or dissimilarity. Many of these amino acid transporters have been first described as transport systems in tissues or cell cultures and were only over the past few years identified on the molecular level. Very recently, a new large family of heterodimeric amino acid transporters has emerged that is unique in its functional and molecular properties. Unlike any other amino acid transporter known so far, these transporters consist of two subunits, a light chain and a heavy chain. Functionally, all heterodimeric amino acid transporters prefer antiport mechanisms leading to exchange of amino acids.
A few recent reviews described the cloning and some functional characteristics of the heterodimeric amino acid transporters (97, 149, 150). However, in the meantime, new subunits have been identified, and progress has been made identifying functional properties and understanding the physiological role of these transporters. This review will, therefore, give a short overview of the heterodimeric amino acid transporters known thus far, their functional properties, their proposed physiological role, their pathophysiological significance, and molecular interaction of the subunits. Because most transporters have been also cloned from human tissue, the discussion of functional properties of these clones will refer to data obtained from the human clones where possible.
Several nomenclatures have been proposed for the new subunits (117, 149). This review, however, will use the nomenclature most widely accepted, which is based on the nomenclature of the different amino acid transport activities as introduced and described by Christensen et al. (29, 30) and also used in a recent review by Palacin et al. (98). Besides historical reference, this nomenclature bears the advantage that the name of the transporter subunit indicates the transport activity expressed by the protein. In general, Na+-dependent transport activities are described with a capital letter, and Na+-independent transport activities are described with a lowercase letter (note the exception of system L, which is Na+ independent).
![]() |
STRUCTURAL FEATURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The Heavy Chains rbAT and 4F2hc
The first subunit of the heterodimeric amino acid transporter family to be identified was rbAT (related to b0,+ amino acid transporter; see System b0,+), which was isolated by expression cloning independently by three groups (7, 138, 157). On the basis of its homology, the second heavy subunit, the 4F2 heavy chain (4F2hc), was identified (5, 158) and characterized as either part of system y+L or system L (5, 15, 19, 20). However, 4F2hc had been previously identified and cloned as a surface antigen on activated lymphocytes and was later renamed CD98 (62, 76, 114, 139).Two transcripts of rbAT mRNA have been identified: a short (~2.3 kb) and a long (~4 kb) transcript differing in 3'-untranslated region (79, 159). The coding sequence of both variants is identical.
The human heavy chain rbAT (SLC3A1) and 4F2hc (SLC3A2) consist of 685 (~85 kDa, glycosylated; 78 kDa, unglycosylated) and 529 (~94 kDa, glycosylated; 72 kDa unglycosylated) (5-7, 54, 87, 98, 155, 157, 158) amino acids, respectively, and have an identity of ~30% (~50% similarity) (5). Analysis of the amino acid sequences suggests that both heavy chains have only one transmembrane helix, that the NH2 terminus is intracellularly localized (5, 7), and, hence, the COOH terminus is extracellularly located. Both proteins have, therefore, been classified as type II membrane proteins. The topology has not been rigorously probed. Studies with epitope-specific antibodies suggest that rbAT may have four transmembrane helices (86). Ample glycosylation of rbAT and 4F2hc clearly indicates that a large part of the COOH terminus is located extracellularly. More studies to resolve this problem are needed. A part of rbAT and 4F2 is structurally related to glycosidases, but glycosidase activity has not yet been demonstrated (157).
On the basis of the structural model of only one transmembrane helix that seemed to be unable to form a transmembrane transporter pore and the lack of amino acid transport activity upon expression of 4F2, and, in particular, rbAT in most cell lines, it was soon postulated that additional subunits were needed for a functional amino acid transporter (18, 45, 98, 99).
The Light Chains
Seven lights chains (LAT1, LAT2, y+LAT1, y+LAT2, ascAT1, xCT, and b0,+AT) have been identified (see also Figs. 1 and 2 and Table 1). On the basis of homology and hydropathy plots, the light chains have 12 transmembrane domains with the NH2 and COOH termini located intracellularly (3, 4, 25, 47, 52, 68, 80, 103, 104, 108, 116, 117, 121, 126, 130, 142). Although the topology has not been addressed experimentally, it is beyond doubt that in contrast to the heavy chains, the light chains display the typical helix bundle structure of membrane transport proteins. The light chains belong to the large superfamily of amino acid/polyamine/choline transporters that occur in nematodes, yeast, bacteria, and mammals (for review, see Ref. 149 and http://www.biology.ucsd.edu/~msaier/transport/). The most closely related family of transporters related to the light subunits is the family of CAT transporters encoding cationic amino acid transporters of the system y+ family (149). Despite the sequence similarity, no interaction between CAT family transporters and 4F2hc or rbAT has been observed (Bröer, unpublished data). In contrast to the light chain family members, CAT-type transporters are thought to span the membrane 14 times. The first 12 helices are similar in both families, suggesting that the CAT transporters have two additional helices on the COOH terminus. Whether these allow 4F2hc-independent trafficking is not known. All light subunits share at least 40% identity (see Fig. 2) with the largest differences in the NH2 and COOH termini (Fig. 1). Little information on functionally or structurally important residues is available at this point. Mutation of G54 to valine and L334 to arginine in the y+LAT1 light chain generates a nonfunctional transporter, thereby causing the phenotype of lysinuric protein intolerance (see Lysinuric Protein Intolerance). The protein is still translocated to the plasma membrane. Both residues are highly conserved in all light chain sequences; G54 resides in helix 1, whereas L334 is located in the loop between helices 8 and 9 (47, 89). Several mutations in the b0,+AT subunit causing non-type I cystinuria lead also to highly diminished or completely abolished transport activity in rbAT-b0,+AT-transfected cells (48, 50).
|
|
|
Interactions Between the Subunits
The most prominent structure involved in the interaction between heavy and light chains is a disulfide bridge between C109 in 4F2hc and C114 in rbAT, respectively, and a conserved cysteine between the transmembrane helices TM3 and TM4 in the different light subunits (80, 90, 105, 155). However, the functional role of the disulfide bridge remains elusive. It appears to be needed neither for the trafficking of the transporter to the membrane nor for the function of the amino acid holotransporter, as shown for the 4F2hc/LAT1 and rbAT heteromers expressed in Xenopus oocytes (34, 90, 105, 154). Pfeiffer et al. (105) found a reduction in expressed transport activity after abolishing the disulfide bridge between 4F2 and Xenopus LAT1; however, other groups could not find such a decrease in transport activity or surface expression (90, 154). Surprisingly, it appears that the disulfide bridge allows crosslinking to light chains, which may not be the physiological partners of the corresponding heavy chain. For example, 4F2hc, when overexpressed, interacts with b0,+AT in mammalian cells (115, 117) and with the oocyte endogenous b0,+AT-like light chain (15). The physiological significance of these observations has yet to be established because 4F2hc has a predominantly basolateral localization, whereas rbAT/b0,+AT is found on the apical membrane (see System b0,+). The function of the disulfide bridge became more obvious when progressive COOH-terminal truncations of the rat rbAT were studied (34). A truncation (
|
The significance of the heavy chain COOH terminus in light chain recognition is supported by functional analysis of truncated versions of 4F2hc. Removal of the COOH-terminal 70 amino acids caused a complete loss of interaction with light chain y+LAT2 and LAT2. By contrast, light chain LAT1 was still translocated to the plasma membrane by a 4F2hc remnant of 133 amino acids, almost as efficient as by the wild-type protein (14), suggesting that recognition of the several 4F2hc-associated light chains requires different domains. Further experiments indicated that the extracellular portion, but not the transmembrane or cytoplasmic parts of 4F2hc, is necessary for interaction with LAT1 (49). The cytoplasmic and transmembrane regions, however, seem to be essential for interaction with integrins (Ref. 49, see REGULATION OF HETERODIMERIC AMINO ACID TRANSPORTERS AND POSSIBLE ROLE IN CELL GROWTH, DIFFERENTIATION, AND CANCER).
Recent observations suggest that the disulfide bridge is important for the regulation of a 4F2-associated cation channel (154). The pharmacology of this cation conductance was unique and resembled only partly the other described cation conductance identified at the basolateral site of the distal tubule and A6 cells (21, 151). In contrast with other transporter-associated conductances (e.g., 17, 46), the 4F2/LAT1-induced cation conductance is not gated by transporter substrates, suggesting either two different permeation pathways or the induction of an endogenous Xenopus cation channel.
Together, it appears that noncovalent bonds dominate the interaction between light and heavy chains. The function of the disulfide bridge remains elusive. It may stabilize the complex in the plasma membrane or could be involved in regulation of associated proteins.
Most mutations in rbAT affect the trafficking of the associated light chain to the plasma membrane, whereas mutations in the b0,+AT light chain result in nonfunctional transporters (47). Similarly, 4F2hc translocates as many as six different light chains to the plasma membrane, each displaying different substrate specificity. Hence, it seems to be obvious that the specificity and the characteristics of the respective amino acid transport systems are mainly determined by their light chains. However, recent investigations of rbAT mutants suggest that the rbAT heavy chain may also be involved in or modulate the transport characteristics of the holotransporter. Two mutations of the rbAT subunit alter the exchange mode and the apparent affinity for neutral amino acids of the system b0,+ transporter. One of these mutations changes a COOH-terminal cysteine residue, C673, and alters the apparent affinity for neutral amino acids. In agreement with these results, it was found that mutation of cysteines in the COOH-terminal part of rbAT rendered amino acid transport less sensitive to inhibition by N-ethylmaleimide, which suggests that these cysteines may form part of the translocation pathway (102).
Further evidence for the involvement of rbAT in the transport process is the observation that the kinetic constants and substrate specificity of the b0,+AT-mediated amino acid transport differ depending on the coexpressed heavy chain (115, 117). When coexpressed with 4F2 in mammalian cells, b0,+AT mediated glutamine transport, whereas when coexpressed with rbAT, glutamine was not recognized as a substrate. Michaelis-Menten constant (Km) values for all substrates were significantly lower in the presence of 4F2 compared with coexpression with rbAT (115).
Although more difficult to rationalize, but in line with the notion of rbAT being a functional domain of the b0,+ transporter, it was found that mutations in b0,+AT causing non-type I cystinuria were all located in the transmembrane or cytosolic domains. This could suggest that the extracellular loops of the b0,+AT light chains are less important for transport function than some rbAT mutations. Moreover, all light chains are nonglycosylated, although the corresponding motifs occur in extracellular loops (67).
![]() |
FUNCTIONAL ASPECTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
System L
System L conveys the Na+-independent transport of large branched and aromatic neutral amino acids in almost all types of cells. System L is differentiated against related transporters by its ability to transport the two model substances, 2-aminobicyclo-(2,2,1)heptane-2-carboxylic acid (BCH) and 3-aminobicyclo(3,2,1)octane-3-carboxylic acid. On the basis of the affinity for its substrate, two subtypes have been described; L1, with a high affinity in the micromolar range, and L2, with a lower affinity in the millimolar range (156). System L transport activity has been described in a variety of cells and organs.The first evidence that system L is associated with expression of 4F2 came from Xenopus laevis oocyte expression experiments in which Bröer et al. (19, 20) observed that poly(A)+ RNA-induced system L activity was abolished by 4F2hc antisense cRNA or antisense oligonucleotides. In 1998, two groups independently identified the first light subunit interacting with 4F2 to form system L (68, 80). Kanai et al. (68) used an expression cloning approach, whereas Spindler et al. (134) identified system L while screening for aldosterone-induced genes in the Xenopus A6 cell line. The isolated amino acid permease-related gene (ASUR4) did not induce any transport activity upon expression in Xenopus oocytes. When coexpressed with 4F2, however, system L activity was induced (80). The cloned transporter was eventually named LAT1. Subsequently, a second cDNA was identified, and, on the basis of its homology, named LAT2 (4, 108, 116, 121, 130). Other groups identified LAT1 as the light chain forming part of the CD98 lymphocyte surface antigen (78, 90, 145).
LAT1 is widely expressed in nonepithelial cells such as brain, spleen, thymus, testis, skin, liver, placenta, skeletal muscle, and stomach (68, 90, 112). In the brain, LAT1 expression is found predominantly in the endothelial cells forming the blood-brain barrier (9, 66). The human LAT1 forms a protein of 507 amino acids, having a molecular mass of 55 kDa (68, 80, 112). 4F2/LAT1 induces Na+-independent transport of large neutral amino acids with Km values in the micromolar range (68, 80, 112). Amino acid transport is inhibited by BCH, as expected for system L (68, 80). The Km values differ depending on the site of the membrane studied. Phenylalanine appears to be a good release substrate but leucine a very poor one, whereas for uptake, leucine is a very good substrate (150). All studies indicate that LAT1 is an obligatory exchanger, at least when expressed in oocytes.
4F2 brings LAT1 to the plasma membrane. In the absence of 4F2, LAT1 is found in intracellular compartments, whereas 4F2 can reach the plasma membrane independently (80, 90). The pattern of surface expression of 4F2 was altered in the presence of LAT1, confining it to cell-cell adhesion sites (90).
The second isoform for system L, LAT2, a protein of 535 amino acids, is highly expressed in polarized epithelia, suggesting an important role in transepithelial amino acid transport (4, 108, 116, 121, 130). The mRNA was identified in kidney, small intestine, testis, prostate, ovary, brain, skeletal muscle, and placenta. Immunolocalization showed basolateral staining in the mouse kidney proximal tubule and small intestine and colocalization with 4F2hc (121). The heavy subunit 4F2 is necessary for trafficking of LAT2 to the oocyte membrane (108, 130). Expression of LAT2 and 4F2 induces amino acid transport with system L characteristics, namely, Na+-independent transport of neutral amino acids sensitive to classic system L inhibitors (108, 121, 130). However, amino acid specificity and apparent affinity are different for LAT2 compared with LAT1. LAT2 also transports small neutral amino acids such as L-alanine, L-glycine, L-cysteine, and L-serine and also glutamine, all of which are poor substrates for LAT1. The apparent affinities for all substrates are severalfold higher compared with those of LAT1 (108, 116, 121, 130). Similar to LAT1, several features of the LAT2 transporter are not fully understood and are at variance with observations in mammalian cells. Some substrates, particularly leucine, show lower affinity for LAT2 than for LAT1, suggesting that LAT2 might be the correlate of the system L2 defined in the liver (108). However, studies in mammalian cells indicate Km values in the millimolar range, whereas those measured for LAT2 are still well below 1 mM for most substrates (121, 130). Moreover, it is controversial whether or not LAT2 mediates uniport of amino acids (108, 116, 121, 130). Considering the basolateral expression in polarized epithelia as the proximal tubule and small intestine and the ability of LAT2 to transport small neutral amino acids, a role in the transepithelial transport of these amino acids has been suggested (108, 121, 130). In particular, the transport of cysteine could provide the basolateral efflux pathway of this amino acid, which is intracellularly formed from cystine taken up by the apical system b0,+ that is defective in cystinuria (108).
In the placenta, system L activity was identified at the apical and basolateral sites of the syncytiotrophoblast, with characteristics of LAT1 at the apical site and LAT2-mediated transport at the basolateral site. However, there has been no protein localization carried out to confirm the apical localization of LAT1. The transport of tryptophan by system L is an important feature of the syncytiotrophoblast. This amino acid is needed as a substrate for the enzyme indoleamine 2,3-dioxygenase, which is responsible for suppressing the maternal immune response to the allogenic murine fetus (72, 73). 1-Methyltryptophan, a blocker of indoleamine 2,3-dioxygenase activity, is a transport inhibitor of system L-mediated tryptophan uptake; blocking of system L by other inhibitors also abolished indoleamine 2,3-dioxygenase activity, suggesting that system L-mediated tryptophan uptake is rate limiting for the activity of the enzyme and plays an important role in maintaining pregnancy (72, 73).
System y+L
System y+L was first functionally described in erythrocytes (37, 39). Further investigation and reevaluation of earlier data revealed its presence in placenta (42, 53, 94), platelets (82), skin fibroblasts (33, 131), hepatocytes (118), small intestine (36), and kidney (118, 119). In polarized epithelia, system y+L is basolateral and allows for the efflux of dibasic amino acids in exchange for preferably large neutral amino acids and Na+. The transport of dibasic amino acids occurs with high affinity with apparent Km values in the range of 5-10 µM (38, 39). In the absence of Na+, exchange of intracellular dibasic with extracellular dibasic amino acids occurs (39). Neutral amino acids are only poorly transported in the absence of Na+, and the transporter is less able to differentiate different neutral amino acids. Li+ potentiates neutral amino acid binding but there is also a loss in selectivity (38). This transport pattern distinguishes system y+L from the dibasic amino acid transport system y+ (38, 39). On a molecular basis, two isoforms of system y+L have recently been identified, y+LAT1 and y+LAT2 (104, 142). Both subunits interact with the 4F2hc to form the systems y+L1 and y+L2 (16, 45, 67, 104, 142).Human y+LAT1 is a protein consisting of 511 amino acids with a predicted molecular mass of ~56 kDa (104, 142). Its mRNA was found mainly in kidney and small intestine, and, to a lesser extent, in peripheral blood lymphocytes, liver, pancreas, epididymis, testis, ovary, placenta, lung, and thyroid. Functionally, y+LAT1 obeys an obligatory exchange mechanism, transporting dibasic amino acids in the absence of Na+ and neutral amino acids in the presence of Na+ (67, 104, 142). Na+ serves to increase the affinity for neutral amino acids without altering the maximal velocity of the transporter (67, 142). In the absence of Na+, protons may substitute for Na+ and drive transport, also increasing the affinity for neutral amino acids (67). Na+ and H+ are both cotransported in a 1:1 stoichiometry with neutral amino acids. However, H+ transport occurs only under nonphysiological conditions, i.e., in the absence of extracellular Na+ (67). It seems that y+LAT1 preferentially mediates the efflux of arginine, which may be important in the kidney, where arginine is produced from citrulline and released into the blood to supply the rest of the body with this amino acid (16, 104). Mutations in y+LAT1 cause the autosomal recessive disease lysinuric protein intolerance (see Lysinuric Protein Intolerance) (10, 143).
The second isoform, y+LAT2, constitutes a protein of 515 amino acids with ~56 kDa molecular mass (142).
Expression (mRNA) was found in brain, testis, and parotis and was found
weaker in small intestine, kidney, and heart. A very weak signal was
obtained from lung and liver (16). In the brain,
y+LAT2 was expressed in both neurons and astrocytes.
Expression was much stronger in the embryonic brain and declined in
adult brain (16). Recently, expression in skin fibroblasts
has been reported (33). y+LAT2 displays the
same mechanism as y+LAT1 but differs in substrate
specificity (16). Besides cationic amino acids, it prefers
large neutral amino acids with bulky side chains. The transport of
y+LAT2 displays strong asymmetry for its substrates:
arginine is a good substrate for uptake and efflux, whereas leucine and
glutamine are easily taken up but are not released. For those
substrates, a 1:1 stoichiometry was measured. This points to a function
of y+LAT2 as an electroneutral arginine/glutamine exchanger
(16). y+LAT2 bears some resemblance to system
x
Neither of the two cloned isoforms of system y+L display the high affinity for dibasic amino acids as reported initially from erythrocytes and other tissues (16, 38, 105, 142). Furthermore, erythrocytes from patients with a genetic defect in the SLC7A7 gene encoding for y+LAT1 (lysinuric protein intolerance) have normal system y+L activity and do not express the second y+L isoform y+LAT2 (11). This suggests that a third, not yet identified, isoform of system y+L may exist.
System asc
The first description of system asc came from erythrocytes, where it was identified as a Na+-independent transport system for short chain neutral amino acids (2, 43, 146). The identification of the 4F2 light chain (4F2lc) family eventually resulted in the isolation of a new light chain with properties close to those expected for system asc and was hence named asc1 (52). The asc1 cDNA encodes a protein of 523 amino acids with a molecular mass of ~53 kDa and is most closely related to LAT2 (see Fig. 1). The human gene was mapped to chromosome 19q12-q13.1 (91). RNA was found in human kidney, brain, placenta, heart, skeletal muscle, lung, liver, and pancreas (91). Studies on the mouse isoform indicate expression in brain, kidney, placenta, small intestine, and lung (52). However, expression appears to be strongest in brain and kidney.System asc conveys the Na+-independent high-affinity
transport of small neutral amino acids such as L-serine,
L-alanine, L-cysteine, L-glycine,
and L-threonine. The transport is strongly inhibited by
different alanine analogs such as 2-aminoisobutyric acid, which is also
a substrate. However, -(methylamino)isobutyric acid has no effect on
transport (52). Functionally important, system asc also
accepts, with a high affinity, the D-isomers
D-serine and D-alanine. D-Serine
plays an important role in the central nervous system since it is
required for the activation of the glutamate
N-methyl-D-aspartate receptor. Furthermore,
L-serine and L-glycine may play an important
role as trophic factors for cerebellar Purkinje cells
(55). Importantly, the affinity of asc1 for
D-serine lies within the physiological concentration of
D-serine in the cerebrospinal fluid (52). In
contrast to all other members of the 4F2lc family, significant uniport
activity was detected in asc1/4F2hc-expressing Xenopus
oocytes (52).
System x
Expression cloning identified xCT and 4F2hc as the two subunits forming
system x
System b0,+
System b0,+ was first described by Van Winkle et al. (147, 148) in mouse blastocysts as a Na+-independent transport system for neutral and dibasic amino acids. It has attained much interest over the last few years because a defect in human kidney system b0,+ causes the inherited hyperaminoaciduria cystinuria (see Cystinuria). Human b0,+ transport activity is characterized by the Na+-independent transport of neutral and dibasic amino acids, including cystine, which is not a substrate of the mouse b0,+ system in blastocysts (148). Vesicle studies from proximal tubules and microperfusion experiments demonstrated that a high-affinity system for cystine was shared with dibasic amino acids, and a low-affinity transport system was not shared (51, 81, 129, 152, 153). In the jejunum, only one common high-affinity system was described (96). These studies agree with flux studies demonstrating the expression of a b0,+-like transport activity in the small intestine (77, 88). The high-affinity transport system in the kidney involved heteroexchange of cystine for lysine (81) and was localized to the straight portion of the proximal tubule (S3 segment) (127). Cystine transport competed with several neutral amino acids (152, 153). It was also concluded that cysteine was not a substrate of these transport systems and was taken up by an alternative system and/or converted to cystine in the lumen (152, 153).On a molecular basis, rbAT (also named NBAT or D2) was first identified by expression cloning as a possible subunit of this system (6, 7, 74, 138, 157). Expression of rbAT in oocytes induced Na+-independent transport of neutral and dibasic amino acids and cystine. The transport system that is induced by rbAT expression in oocytes has a high affinity for dibasic amino acids and cystine in the 20-80 µM range and a lower affinity for neutral amino acids in the 0.2 mM high millimolar range (6, 7, 22, unpublished data). The fact that the transport of neutral amino acids caused outward currents (net outward movement of positive charges) and the transport of dibasic amino acid caused inward currents (net inward movement of positive charges) led to the discovery that system b0,+ was an obligatory exchanger (22, 27, 31). The transport of cystine and the suppression of cystine transport in the OK cell line after a partial knock out of rbAT (85) led to the subsequent identification of rbAT as a gene involved in cystinuria (see below).
rbAT interacts with the recently cloned light chain b0,+AT to form the complete transporter for system b0,+ (25, 48, 103). The human b0,+AT protein has only 487 amino acids, with a predicted molecular mass of 54 kDa (25, 47, 103, 117). b0,+AT mRNA is expressed in kidney and small intestine, and, to a smaller extent, in heart, liver, placenta, and lung (25, 47, 103, 117). Immunostaining in the kidney, however, revealed different localization along the nephron. rbAT protein was found in the apical membrane of the renal proximal tubule, increasing from the S1 to the S3 segment and in the microvilli of the small intestine (25, 69, 87, 103, 106). b0,+AT protein, however, is also expressed in the apical membrane of the proximal tubule, but expression levels decrease from the S1 to the S3 segment (25, 103, 115). Given the promiscuity of the light chain/heavy chain interaction as outlined above, it is tempting to speculate that rbAT and b0,+AT subunits may have additional partners in the proximal tubule. The OK and LLC-PK1 kidney cell lines and the colon carcinoma Caco-2 cell line also express rbAT (85, 141, 157, 159). It therefore seems beyond doubt that the above- described high-affinity cystine transport observed in kidney and intestine is mediated by the rbAT/b0,+AT heterodimer. Surprisingly, the mouse b0,+AT subunit induces cystine transport when coexpressed with rbAT, suggesting the presence of yet unknown light chains in mouse blastocysts. Besides expression in kidney and intestine, rbAT mRNA or protein has been localized in pancreas (6), heart (159), adrenal gland (92), brain stem, and spinal cord (92, 106, 159). However, in part of the brain cells, rbAT was localized to intracellular membranes (92, 106). Some of the neurons also contained constitutive nitric oxide synthase, and it was therefore discussed whether rbAT may be involved in providing arginine for nitric oxide synthesis (107, 136). The relevance of these observations has to be discussed in view of much more limited distribution of the b0,+ subunit, supporting the notion that rbAT may interact with other light chains in these cell types. Vice versa, b0,+AT may interact with 4F2hc in liver cells.
The functional characterization of the rbAT/b0,+AT heterodimer proved to be difficult because the usual expression system, X. laevis oocytes, exhibit a very strong endogenous b0,+-like transport activity upon expression of rbAT alone, which is almost indistinguishable from its mammalian counterpart. Pfeiffer et al. (103), therefore, constructed a fusion protein linking the NH2 terminus of rbAT with the COOH terminus of b0,+AT. This protein induced b0,+-like transport activity in Xenopus oocytes and demonstrated Na+-independent, high-affinity transport of dibasic amino acids and cystine and low-affinity transport of neutral amino acids. Feliubadalo et al. (47) and Chairoungdua et al. (25) alternatively demonstrated functional expression of the two subunits in COS cells and showed that each protein reached the plasma membrane only in the presence of both subunits and exhibited the same features of b0,+-like transport activity as expected.
Transport by the rbAT/b0,+AT heterodimer obeys an
obligatory exchange mechanism for neutral and dibasic amino acids.
Three factors contribute to the asymmetry of the transporter to
accomplish the reabsorption of dibasic amino acids and cystine. The
affinity for dibasic amino acids and cystine is severalfold higher than for neutral amino acids (7, 22, 103, unpublished data), the negative membrane potential favors the inward transport of dibasic amino acids
in exchange for neutral amino acids, and there is a strong chemical
gradient for cystine. Cystine is rapidly reduced to cysteine intracellularly, which may leave the cell basolaterally through the
LAT2 transporter (Fig. 4) (27, 108,
135).
|
![]() |
REGULATION OF HETERODIMERIC AMINO ACID TRANSPORTERS AND POSSIBLE ROLE IN CELL GROWTH, DIFFERENTATION, AND CANCER |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Little is known about regulation of the heterodimeric amino acid
transporters. Besides the fact that the first member of this family,
LAT1, was identified as an aldosterone-regulated gene (134) in the Xenopus cell line A6, the
significance of this still unclear, studies on the regulation of these
transporters have only started. Even though it is well documented that
some of the described transport activities are highly regulated
(29), the most interesting question, how this regulation
occurs, still needs to be addressed. A few recent studies shed some
light on this question. Because heterodimeric transporters are
constituted of two different proteins, synthesis of both subunits might
be regulated. Indeed, some studies indicate that 4F2 is the main
regulator of activity, whereas other studies indicate that regulation
occurs on the level of the light chain. Kudo et al.
(71) studied regulation of systems L, y+L, and
y+ in human placental trophoblasts, which are known to
induce these systems after taking to culture. They found an increase
only in 4F2 and CAT1 mRNA but not in LAT1, LAT2, y+LAT1,
and y+LAT2. Unfortunately, nothing is known about protein
levels and a possible translocation/trafficking of existing protein
(71). This finding would suggest that regulation involves
mainly 4F2. A second study in the kidney, however, comes to a different
conclusion. In the kidney, activation of the basolateral, rate-limiting
system y+L, but not system L, was observed in
dexamethasone-treated rats. Schwertfeger et al. (128)
found upregulation of 4F2 protein expression and a similar increase in
y+LAT1 mRNA, suggesting that the enhanced expression of
both subunits is necessary for upregulation of y+L
transport activity. Furthermore, regulation of LAT1 was observed in
hepatocytes in which 2,3,7,8-tetrachlorodibenzo-p-dioxin
increased LAT1 transcription and system L amino acid transport
(123). However, no information about 4F2 regulation was
provided. The regulation of system x
On the other hand, expression of LAT1 is regulated by amino acid availability. Surprisingly, arginine, not a substrate of LAT1, has the most profound effect on transcription. The regulation is lost in transformed cell lines (24). Another piece of evidence for an involvement of 4F2/LAT1 in the control of amino acid fluxes is that overexpression of 4F2 causes transformation of BALB/3T3 cells (132) and that activation of lymphocytes is accompanied by an upregulation of 4F2 (20, 140). Induction of 4F2 in lymphocytes occurs very early upon proliferative stimuli such as Ca2+ or protein kinase C activation (140). The light chain LAT1 is highly expressed in a number of tumor cell lines (68, 90, 114) and appears to be concomitantly regulated with 4F2. Different antibodies directed against 4F2 block lymphocyte and tumor cell proliferation (38). Furthermore, there seems to be a correlation between the expression of 4F2 and the proliferative activity of cells, as described for skin keratinocytes, melanoma cells, Langerhans cells, and intestinal epithelia (38). Besides a possible role in cell proliferation, a role in cell differentiation has been proposed. In addition, overexpression of 4F2/LAT1 seems to induce malignant transformation in NIH/3T3 fibroblasts (61, 132). The common point for these observations may be the fact that amino acid availability may control mRNA synthesis and proliferation (64) and that the flow of amino acids through 4F2/LAT1 is a prerequisite for the described events (37). At variance with this proposed function, all studies have indicated thus far that LAT1 obeys an obligatory antiport mechanism that is not compatible with a net uptake of essential amino acids, which has been demonstrated, e.g., at the blood-brain barrier (100) and which is necessary for cell growth. However, transport rates determined in cultured mammalian cells are usually severalfold higher than metabolic rates. A small percentage of uniport activity might, therefore, suffice to sustain cell growth. The low temperature used in oocyte experiments might obscure such a low activity of the studied transport systems. In the case of the obligatory antiporter ASCT2, it was recently shown that alanine displayed significant uniport activity (13).
4F2 has also been reported to associate with integrins and regulate their activation through the cytoplasmic and transmembrane regions (26, 48, 49). Integrins are involved in a variety of cellular functions such as cell growth, migration, and tumor metastasis. This interaction may involve the induction of membrane protein clustering, allowing for interaction among proteins, and, therefore, inducing intracellular signaling (37). The above-mentioned ability of 4F2hc/LAT1 to cause malignant transformation when overexpressed, which is difficult to reconcile with an increase in amino acid transport only, might, therefore, be conditional on the ability of 4F2hc to interact with other proteins, such as integrins. Moreover, it could be demonstrated that 4F2hc is the fusion regulatory protein-1 that plays an important role in the fusion of cells and may be required for virus-induced cell fusion (95, 144). However, it may be the case that the virus misuses a cell surface protein for attachment. Antibody binding to 4F2 or CD98 triggers the activation of protein kinases, the mechanism of which is not understood (137). It is tempting to speculate that the heterodimeric construction of this family of transporters, rather than being necessary for amino acid transport itself, ensures an integration of events in cell proliferation and differentiation with a change in amino acid transport activity.
Role of Heterodimeric Amino Acid Transporters in Monogenic Diseases
In contrast to the diffuse role of 4F2/LAT1 in cell proliferation, a loss of function carried out by members of the heterodimeric amino acid transporters results in well-described failures of reabsorption of amino acids in kidney and intestine, known as cystinuria and lysinuric protein intolerance, respectively. However, the phenotypes of these two diseases, which have been genetically linked to the rbAT/b0,+AT complex and the y+LAT1 subunit, respectively, shed light on the function of these transporters and their interaction with other transporters. Brief descriptions of both diseases are given below, and the role of the involved subunits is discussed. For a more detailed review of these diseases, refer to a recent review (97).Cystinuria
Cystinuria is an inherited hyperaminoaciduria (OMIM 220100 and OMIM 600918) of cystine and the dibasic amino acids arginine, lysine, and ornithine. Because the solubility of cystine is very low, particularly in acid fluids, cystine precipitates and forms recurrent cystine kidney stones. These stones can occur beginning very early in childhood and continue, leading to progressive renal failure due to recurrent urinary infections and slow destruction of renal parenchyma. Cystinuria accounts for 1-2% of nephrolithiasis in adult patients and for ~6-8% in pediatric patients. The estimated prevalence is 1 in 7,000 newborns, with a higher prevalence in Libyan Jews of ~1 in 2,500 and a lower prevalence in Sweden, with ~1 in 100,000 newborns (97).The transport defect lies in the brush-border membrane of the renal proximal tubule and small intestine and leads to reduced renal and intestinal reabsorption of cystine, arginine, ornithine, and lysine. Because these amino acids can be formed by metabolism or taken up by other transporters, the defect does not cause malnutrition. Early functional data suggested the existence of three distinct subtypes of cystinuria according to the excretion patterns and intestinal absorption of the amino acids in heterozygotes, i.e., the unaffected siblings of a cystinuria patient carrying only one affected allele (120). Heterozygous siblings from non-type I cystinuria patients show elevated urinary excretion levels and reduced intestinal absorption of cystine and dibasic amino acids, whereas heterozygous siblings from type I cystinuria patients show no defects. On a molecular level, however, only two forms of cystinuria can be distinguished thus far: cystinuria type I, caused by mutations in the heavy subunit rbAT (SLC3A1) (1, 23, 41, 44, 56, 83, 109, 111, 122), and cystinuria non-type I, with mutations in the light subunit b0,+AT (SLC7A9) (47). More than 60% of all cystinuria cases worldwide are type I (97). The fact that unaffected carriers of type I cystinuria show a normal amino acid excretion pattern defines this type as autosomal recessively inherited. In contrast, heterozygotes for SLC7A9 mutations have elevated amino acid excretion, which led to the assumption of an incomplete autosomal recessive inheritance.
Up to now, >50 mutations and 10 polymorphisms in the SLC3A1 gene have been identified, giving rise to large deletions, premature stop codons, or missense mutations (1, 8, 23, 35, 41, 44, 56-60, 63, 83, 110, 111, 113, 122). The two most common mutations are M467T or M467K and T216M; the M467T/K mutation is predominantly found in Spanish and Italian patients (24, 36), whereas the T216M mutation is mainly identified in Greek patients (1). These results suggest a population-specific distribution, as previously described for cystic fibrosis transmembrane conductance regulator mutations in cystic fibrosis (1). Of these missense mutations, only a few have been functionally characterized. M467T and M467K show a reduced expression in Xenopus oocytes that is fully restored either with increasing injected RNA concentrations or prolonged periods of expression. The mutant is not fully glycosylated and, therefore, causes a defective trafficking of the otherwise fully functional subunit to the membrane (28). Subsequently, a number of studies examined seven other missense mutations on the basis of only their expression rate and concluded these to be also trafficking mutants (83, 111, 122). However, two mutations, R365W and C673S, were recently identified that also altered the functional characteristics of the b0,+-like transport system, suggesting that rbAT is not only important for the trafficking of the transporter to the membrane. For some mutations, no functional defect could be identified, which may be due to the oocyte expression system. It is well known that conformational changes in a protein leading to translocation defects can be partially overcome by reducing the incubation temperature.
In the light subunit SLC7A9 (b0,+AT), 35 mutations were found (47, 50); the most common, V170M, completely abolished amino acid transport when cotransfected with rbAT into COS cells (47). Font et al. (50) suggested a correlation between the phenotype and the mutation, showing that some mutations with residual transport activity correlated with lower amino acid excretion levels and thus with a less severe disease phenotype. The milder mutations affected amino acids that were not highly conserved, whereas the severe mutations were found in highly conserved regions (50). Recently, the V170M mutation, which is found mainly in Libyan Jews, has been traced back to one possible founder who lived around the time the Jews settled in Libya after their expulsion from the Iberian Peninsula (32).
Lysinuric Protein Intolerance
Lysinuric protein intolerance (OMIM 222700) is characterized by the defective transport of the cationic amino acids lysine, arginine, and ornithine at the basolateral side of the epithelia in the proximal tubule and small intestine (119). The consequent renal loss and reduced intestinal absorption of these amino acids result in an impaired urea cycle with low blood urea. Therefore, the defect manifests itself with a variety of symptoms such as hyperammonemia after high protein meals, the failure to thrive, hepatosplenomegaly, osteoporosis, pulmonary problems (alveolar proteinosis), and mental deteriorations. Furthermore, lysinuric protein intolerance patients may also suffer from hematological and immunological problems such as hemophagocytotic lymphohistiocytosis (fever, hepatosplenomegaly, hypofibrinogenemia, hypertriglyceridemia, cytopenia) and impaired B cell activity with severe recurrent infections (40, 75). The transport defect has also been described in skin fibroblasts (131). However, a recent report did not find altered amino acid transport in skin fibroblasts from lysinuric protein intolerance patients (33). When untreated, the patients will die. The rare autosomal recessive disease is particularly frequent in Finland (89).Mutations in the SLC7A7 (solute carrier 7, family 7) gene encoding the y+LAT1 protein were found to be causative for this disease. Eighteen mutations, i.e., deletions, frame shifts, missense mutations, and nonsense mutations have been identified thus far in patients (10, 70, 89, 93, 133, 143). Functional studies with some mutations expressed in Xenopus oocytes revealed that only y+LAT1 missense mutations reached the plasma membrane but showed little transport activity. Truncations and frameshifts produced a protein that was unable to reach the plasma membrane (89).
No disease has been identified that is associated with mutations in 4F2. Given its wide distribution and functional importance in amino acid transport across cell membranes and across blood-tissue barriers, it seems likely that nonfunctional mutations result in death at embryonic stages.
![]() |
OPEN QUESTIONS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Work on the role and structure of the heterodimeric amino acid transporters has just begun. Many problems need to be solved, only a few of which are mentioned below.
Structural Aspects
Besides the question of whether all members of this new family have been identified, it will be most interesting to understand how the subunits interact and what confers the specificity of this interaction. Having closely related subunits with very distinct transport characteristics will allow better understanding as to which structural features determine the specificity of each transport system.Functional Aspects
In parallel, we need to learn about the physiological role of the transporters in the different tissues and how transport activity is regulated. The effects of 4F2 heterodimers on ion channel activity, cell proliferation, cell fusion, and cell adhesion are still incompletely described, and the associated proteins are not defined. It is likely that not all light chains and perhaps some heavy chains have not been identified yet. In particular, light chains with increased uniport activity are expected to be expressed at blood-tissue barriers and at the basolateral side of the kidney.Involvement in Health and Diseases
Failure of amino acid reabsorption is the most prominent consequence of amino acid transport failure. Heterodimeric transporters could be important in the maintenance of pregnancy, proliferation of tumor cells, transport of hormones (i.e., thyroid hormones), and drugs. Although amino acid transport is the best-defined function of 4F2hc/lc, there is clear evidence that it is involved in cell proliferation, activation, cell fusion, and differentiation. Provision of an integrated view of these functions is required to cope with the complexity of heterodimeric amino acid transporters and to understand the role each transporter and transport system is playing in its cellular context. ![]() |
ACKNOWLEDGEMENTS |
---|
The authors thank A. Bröer and B. Noll for continuous technical assistance.
![]() |
FOOTNOTES |
---|
This work was supported by grants from the European Community (to F. Lang), the Deutsche Forschungsgemeinschaft (to S. Bröer and F. Lang), and the Federal Ministry of Education, Science, Education, Research, and Technology (01KS9602, IZKF Tübingen to F. Lang and C. A. Wagner).
C. A. Wagner is a Feodor-Lynen fellow of the Alexander von Humboldt Foundation, Germany.
Address for reprint requests and other correspondence: C. A. Wagner, Dept. of Cellular and Molecular Physiology, School of Medicine, Yale Univ., 333 Cedar St., New Haven, CT 06520 (E-mail: wagnerca{at}hotmail.com).
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1.
Albers, A,
Lahme S,
Wagner CA,
Kaiser P,
Zerres K,
Capasso G,
Pica A,
Palacin M,
Lang F,
Bichler KH,
and
Eggermann T.
Mutations in the SLC3A1 gene in cystinuric patients: frequencies and identification of a novel mutation.
Genet Test
3:
227-231,
1999[ISI][Medline].
2.
Albi, JL,
Canals P,
Gallardo MA,
and
Sanchez J.
Na+-independent L-alanine uptake by trout cells. Evidence for the existence of at least two functionally different asc systems.
J Membr Biol
140:
189-196,
1994[ISI][Medline].
3.
Bassi, MT,
Gasol E,
Manzoni M,
Pineda M,
Riboni M,
Martin R,
Zorzano A,
Borsani G,
and
Palacin M.
Identification and characterisation of human xCT that coexpresses, with 4F2 heavy chain, the amino acid transport activity system x
4.
Bassi, MT,
Sperandeo MP,
Incerti B,
Bulfone A,
Pepe A,
Surace EM,
Gattuso C,
De Grandi A,
Buoninconti A,
Riboni M,
Manzoni M,
Andria G,
Ballabio A,
Borsani G,
and
Sebastio G.
SLC7A8, a gene mapping within the lysinuric protein intolerance critical region, encodes a new member of the glycoprotein-associated amino acid transporter family.
Genomics
62:
297-303,
1999[ISI][Medline].
5.
Bertran, J,
Magagnin S,
Werner A,
Markovich D,
Biber J,
Testar X,
Zorzano A,
Kühn LC,
Palacin M,
and
Murer H.
Stimulation of system y+-like amino acid transport by the heavy chain of human 4F2 surface antigen in Xenopus laevis oocytes.
Proc Natl Acad Sci USA
89:
5606-5610,
1992[Abstract].
6.
Bertran, J,
Werner A,
Chillaron J,
Nunes V,
Biber J,
Testar X,
Zorzano A,
Estivill X,
Murer H,
and
Palacin M.
Expression cloning of a human renal cDNA that induces high affinity transport of L-cystine shared with dibasic amino acids in Xenopus oocytes.
J Biol Chem
268:
14842-14849,
1993
7.
Bertran, J,
Werner A,
Moore ML,
Stange G,
Markovich D,
Biber J,
Testar X,
Zorzano A,
Palacin M,
and
Murer H.
Expression cloning of a cDNA from rabbit kidney cortex that induces a single transport system for cystine and dibasic and neutral amino acids.
Proc Natl Acad Sci USA
89:
5601-5605,
1992[Abstract].
8.
Bisceglia, L,
Calonge MJ,
Dello Strologo L,
Rizzoni G,
de Sanctis L,
Gallucci M,
Beccia E,
Testar X,
Zorzano A,
Estivill X,
Zelante L,
Palacin M,
Gasparini P,
and
Nunes V.
Molecular analysis of the cystinuria disease gene: identification of four new mutations, one large deletion, and one polymorphism.
Hum Genet
98:
447-451,
1996[ISI][Medline].
9.
Boado, RJ,
Li JY,
Nagaya M,
Zhang C,
and
Pardridge WM.
Selective expression of the large neutral amino acid transporter at the blood-brain barrier.
Proc Natl Acad Sci USA
96:
12079-12084,
1999
10.
Borsani, G,
Bassi MT,
Sperandeo MP,
De Grandi A,
Buoninconti A,
Riboni M,
Manzoni M,
Incerti B,
Pepe A,
Andria G,
Ballabio A,
and
Sebastio G.
SLC7A7, encoding a putative permease-related protein, is mutated in patients with lysinuric protein intolerance.
Nat Genet
21:
297-301,
1999[ISI][Medline].
11.
Boyd, CAR,
Deves R,
Laynes R,
Kudo Y,
and
Sebastio G.
Cationic amino acid transport through system y+L in erythrocytes of patients with lysinuric protein intolerance.
Pflügers Arch
439:
513-516,
2000[ISI][Medline].
12.
Bridges, CC,
Kekuda R,
Wang H,
Prassad PD,
Mehta P,
Huang W,
Smith SB,
and
Ganapathy V.
Structure, function, and regulation of human cystine/glutamate transporter in retinal pigment epithelial cells.
Invest Ophthalmol Vis Sci
42:
47-54,
2001
13.
Bröer, A,
Brookes N,
Ganapathy V,
Dimmer KS,
Wagner CA,
Lang F,
and
Bröer S.
The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux.
J Neurochem
73:
2184-2194,
1999[ISI][Medline].
14.
Bröer, A,
Friedrich B,
Wagner CA,
Fillon S,
Ganapathy V,
Lang F,
and
Bröer S.
Association of 4F2hc with the light chains LAT1, LAT2 or y+LAT2 requires different domains.
Biochem J
355:
725-731,
2001[ISI][Medline].
15.
Bröer, A,
Hamprecht B,
and
Bröer S.
Discrimination of two amino acid transport activities in 4F2 heavy chain-expressing Xenopus laevis oocytes.
Biochem J
333:
549-554,
1998[ISI][Medline].
16.
Bröer, A,
Wagner C,
Lang F,
and
Bröer S.
The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine.
Biochem J
349:
787-795,
2000[ISI][Medline].
17.
Bröer, A,
Wagner C,
Lang F,
and
Bröer S.
Neutral amino acid transporter ASCT2 displays substrate-induced Na+ exchange and a substrate-gated anion conductance.
Biochem J
346:
705-710,
2000[ISI][Medline].
18.
Bröer, S.
Molecular identification of astroglial neutral amino acid transport systems.
Dev Neurosci
18:
484-491,
1996[ISI][Medline].
19.
Bröer, S,
Bröer A,
and
Hamprecht B.
The 4F2hc surface antigen is necessary for expression of system L-like neutral amino acid-transport activity in C6-BU-1 rat glioma cells: evidence from expression studies in Xenopus laevis oocytes.
Biochem J
312:
863-870,
1995[ISI][Medline].
20.
Bröer, S,
Bröer A,
and
Hamprecht B.
Expression of the surface antigen 4F2hc affects system L-like neutral-amino-acid-transport activity in mammalian cells.
Biochem J
324:
535-541,
1997[ISI][Medline].
21.
Broillet, MC,
Berger A,
and
Horisberger JD.
Early effects of aldosterone on the basolateral potassium conductance of A6 cells.
Pflügers Arch
424:
91-93,
1993[ISI][Medline].
22.
Busch, AE,
Herzer T,
Waldegger S,
Schmidt F,
Palacin M,
Biber J,
Markovich D,
Murer H,
and
Lang F.
Opposite directed currents induced by the transport of dibasic and neutral amino acids in Xenopus oocytes expressing the protein rBAT.
J Biol Chem
269:
25581-25586,
1994
23.
Calonge, MJ,
Gasparini P,
Chillarón J,
Chillón M,
Gallucci M,
Rousaud F,
Zelante L,
Testar X,
Dallapiccola B,
Di Silverio F,
Barceló P,
Estivill X,
Zorzano A,
Nunes V,
and
Palacin M.
Cystinuria caused by mutations in rBAT, a gene involved in the transport of cystine.
Nat Genet
6:
420-425,
1994[ISI][Medline].
24.
Campbell, WA,
Sah DE,
Medina MM,
Albina JE,
Coleman WB,
and
Thompson NL.
TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss of response in tumor cells.
J Biol Chem
275:
5347-5354,
2000
25.
Chairoungdua, A,
Segawa H,
Kim JY,
Miyamoto K,
Haga H,
Fukui Y,
Mizoguchi K,
Ito H,
Takeda E,
Endou H,
and
Kanai Y.
Identification of an amino acid transporter associated with the cystinuria-related type II membrane glycoprotein.
J Biol Chem
274:
28845-28848,
1999
26.
Chandrasekaran, S,
Guo NH,
Rodrigues RG,
Kaiser J,
and
Roberts DD.
Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by 3
1 integrin and regulated by insulin-like growth factor-1 and CD98.
J Biol Chem
274:
11408-11416,
1999
27.
Chillaron, J,
Estevez R,
Mora C,
Wagner CA,
Suessbrich S,
Lang F,
Gelpí JL,
Testar X,
Busch AE,
Zorzano A,
and
Palacín M.
Obligatory amino acid exchange via systems b0,+-like and y+L-like. A tertiary active transport mechanism for renal reabsorption of cystine and dibasic amino acids.
J Biol Chem
271:
17761-17770,
1996
28.
Chillaron, J,
Estevez R,
Samarzija I,
Waldegger S,
Testar X,
Lang F,
Zorzano A,
Busch AE,
and
Palacin M.
An intracellular trafficking defect in type I cystinuria rBAT mutants M467T and M467K.
J Biol Chem
272:
9543-9549,
1997
29.
Christensen, HN.
Role of amino acid transport and countertransport in nutrition and metabolism.
Physiol Rev
70:
43-77,
1990
30.
Christensen, HN,
Albritton LM,
Kakuda DK,
and
Macleod CL.
Gene-product designations for amino acid transporters.
J Exp Biol
196:
51-57,
1995
31.
Coady, MJ,
Jalal F,
Chen X,
Lemay G,
Berteloot A,
and
Lapointe JY.
Electrogenic amino acid exchange via the rBAT transporter.
FEBS Lett
356:
174-178,
1994[ISI][Medline].
32.
Colombo, R.
Dating the origin of the V170M mutation causing non-type I cystinuria in Libyan Jews by linkage disequilibrium and physical mapping of the SLC7A9 gene.
Genomics
69:
131-134,
2000[ISI][Medline].
33.
Dall'Asta, V,
Bussolati O,
Sala R,
Rotoli BM,
Sebastio G,
Sperandeo MP,
Andria G,
and
Gazzola GC.
Arginine transport through system y+L in cultured human fibroblasts: normal phenotype of cells from LPI subjects.
Am J Physiol Cell Physiol
279:
C1829-C1837,
2000
34.
Deora, AB,
Ghosh RN,
and
Tate SS.
Progressive C-terminal deletions of the renal cystine transporter, NBAT, reveal a novel bimodal pattern of functional expression.
J Biol Chem
273:
32980-32987,
1998
35.
De Sanctis, L,
Bruno M,
Bonetti G,
Cosseddu D,
Bisceglia L,
Ponzone A,
and
Dianzani I.
Phenotype characterization and prevalence of rBAT M467T mutation in Italian cystinuric patients.
J Inherit Metab Dis
19:
243-245,
1996[ISI][Medline].
36.
Desjeux, JF,
Simell RO,
Dumontier AM,
and
Perheentupa J.
Lysine fluxes across the jejunal epithelium in lysinuric protein intolerance.
J Clin Invest
65:
1382-1387,
1980[ISI][Medline].
37.
Deves, R,
and
Boyd CAR
Surface antigen CD98(4F2): not a single membrane protein, but a family of proteins with multiple functions.
J Membr Biol
173:
165-177,
2000[ISI][Medline].
38.
Deves, R,
and
Boyd CAR
Transporters for cationic amino acids in animal cells: discovery, structure, and function.
Physiol Rev
78:
487-545,
1998
39.
Deves, R,
Chavez P,
and
Boyd CAR
Identification of a new transport system (y+L) in human erythrocytes that recognizes lysine and leucine with high affinity.
J Physiol
454:
491-501,
1992[Abstract].
40.
Duval, M,
Fenneteau O,
Doireau V,
Faye A,
Emilie D,
Yotnda P,
Drapier JC,
Schlegel N,
Sterkers G,
de Baulny HO,
and
Vilmer E.
Intermittent hemophagocytic lymphohistiocytosis is a regular feature of lysinuric protein intolerance.
J Pediatr
134:
236-239,
1999[ISI][Medline].
41.
Egoshi, KI,
Akakura K,
Kodama T,
and
Ito H.
Identification of five novel SLC3A1 (rBAT) gene mutations in Japanese cystinuria.
Kidney Int
57:
25-32,
2000[ISI][Medline].
42.
Eleno, N,
Deves R,
and
Boyd CAR
Membrane potential dependence of the kinetics of cationic amino acid transport systems in human placenta.
J Physiol
479:
291-300,
1994[Abstract].
43.
Ellory, JC,
Jones SE,
and
Young JD.
Glycine transport in human erythrocytes.
J Physiol
320:
403-422,
1981[Abstract].
44.
Endsley, JK,
Phillips JA,
Hruska KA,
Denneberg T,
Carlson J,
and
George AL, Jr.
Genomic organization of a human cystine transporter gene (SLC3A1) and identification of novel mutations causing cystinuria.
Kidney Int
51:
1893-1899,
1997[ISI][Medline].
45.
Estevez, R,
Camps M,
Rojas AM,
Testar X,
Deves R,
Hediger MA,
Zorzano A,
and
Palacin M.
The amino acid transport system y+L/4F2hc is a heteromultimeric complex.
FASEB J
12:
1319-1329,
1998
46.
Fairman, WA,
Vandenberg RJ,
Arriza JL,
Kavanaugh MP,
and
Amara SG.
An excitatory amino-acid transporter with properties of a ligand-gated chloride channel.
Nature
375:
599-603,
1995[ISI][Medline].
47.
Feliubadalo, L,
Font M,
Purroy J,
Rousaud F,
Estivill X,
Nunes V,
Golomb E,
Centola M,
Aksentijevich I,
Kreiss Y,
Goldman B,
Pras M,
Kastner DL,
Pras E,
Gasparini P,
Bisceglia L,
Beccia E,
Gallucci M,
de Sanctis L,
Ponzone A,
Rizzoni GF,
Zelante L,
Bassi MT,
George AL, Jr,
and
Palacin M.
Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (b0,+AT) of rBAT. International Cystinuria Consortium.
Nat Genet
23:
52-57,
1999[ISI][Medline].
48.
Fenczik, CA,
Sethi T,
Ramos JW,
Hughes PE,
and
Ginsberg MH.
Complementation of dominant suppression implicates CD98 in integrin activation.
Nature
390:
81-85,
1997[ISI][Medline].
49.
Fenczik, CA,
Zent R,
Dellos M,
Calderwood DA,
Satriano J,
Kelly C,
and
Ginsberg MH.
Distinct domains of CD98hc regulate integrins and amino acid transport.
J Biol Chem
276:
8746-8752,
2001
50.
Font, M,
Feliubadalo L,
Estivill X,
Nunes V,
Golomb E,
Kreiss Y,
Pras E,
Bisceglia L,
d'Adamo AP,
Zelante L,
Gasparini P,
Bassi MT,
George AL, Jr,
Manzoni M,
Riboni M,
Ballabio A,
Borsani G,
Reig N,
Fernandez E,
Zorzano A,
Bertran J,
and
Palacin M.
Functional analysis of mutations in SLC7A9, and genotype-phenotype correlation in non-type I cystinuria.
Hum Mol Genet
10:
305-316,
2001
51.
Foreman, JW,
Hwang SM,
and
Segal S.
Transport interactions of cystine and dibasic amino acids in isolated rat renal tubules.
Metabolism
29:
53-61,
1980[ISI][Medline].
52.
Fukasawa, Y,
Segawa H,
Kim JY,
Chairoungdua A,
Kim DK,
Matsuo H,
Cha SH,
Endou H,
and
Kanai Y.
Identification and characterization of a Na+-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids.
J Biol Chem
275:
9690-9698,
2000
53.
Furesz, TC,
and
Smith CH.
Identification of two leucine-sensitive lysine transport activities in human placental basal membrane.
Placenta
18:
649-655,
1997[ISI][Medline].
54.
Furriols, M,
Chillaron J,
Mora C,
Castello A,
Bertran J,
Camps M,
Testar X,
Vilaro S,
Zorzano A,
and
Palacin M.
rBAT, related to L-cysteine transport, is localized to the microvilli of proximal straight tubules, and its expression is regulated in kidney by development.
J Biol Chem
268:
27060-27068,
1993
55.
Furuya, S,
Tabata T,
Mitoma J,
Yamada K,
Yamasaki M,
Makino A,
Yamamoto T,
Watanabe M,
Kano M,
and
Hirabayashi Y.
L-serine and glycine serve as major astroglia-derived trophic factors for cerebellar purkinje neurons.
Proc Natl Acad Sci USA
97:
11528-11533,
2000
56.
Gasparini, P,
Calonge MJ,
Bisceglia L,
Purroy J,
Dianzani I,
Notarangelo A,
Rousaud F,
Gallucci M,
Testar X,
Ponzone A,
Estivill X,
Zorzano A,
Palacin M,
Nunes V,
and
Zelante L.
Molecular genetics of cystinuria: identification of four new mutations and seven polymorphisms, and evidence for genetic heterogeneity.
Am J Hum Genet
57:
781-788,
1995[ISI][Medline].
57.
Gitomer, WL,
Reed BY,
and
Pak CY.
Identification of two novel mutations [P122S (364C>T) and 1601delAC] in the SLC3A1 gene in type I cystinurics.
Hum Mutat
15:
390,
2000[Medline].
58.
Gitomer, WL,
Reed BY,
Ruml LA,
and
Pak CY.
335-Base deletion in the mRNA coding for a dibasic amino acid transporter-like protein (SLC3A1) isolated from a patient with cystinuria.
Hum Mutat Suppl
1:
S69-S71,
1998.
59.
Gitomer, WL,
Reed BY,
Ruml LA,
Sakhaee K,
and
Pak CY.
Mutations in the genomic deoxyribonucleic acid for SLC3A1 in patients with cystinuria.
J Clin Endocrinol Metab
83:
3688-3694,
1998
60.
Goodyer, P,
Saadi I,
Ong P,
Elkas G,
and
Rozen R.
Cystinuria subtype and the risk of nephrolithiasis.
Kidney Int
54:
56-61,
1998[ISI][Medline].
61.
Hara, K,
Kudoh H,
Enomoto T,
Hashimoto Y,
and
Masuko T.
Malignant transformation of NIH3T3 cells by overexpression of early lymphocyte activation antigen CD98.
Biochem Biophys Res Commun
262:
720-725,
1999[ISI][Medline].
62.
Haynes, BF,
Hemler ME,
Mann DL,
Eisenbarth GS,
Shelhamer J,
Mostowski HS,
Thomas CA,
Strominger JL,
and
Fauci AS.
Characterization of a monoclonal antibody (4F2) that binds to human monocytes and to a subset of activated lymphocytes.
J Immunol
126:
1409-1414,
1981
63.
Horsford, J,
Saadi I,
Raelson J,
Goodyer PR,
and
Rozen R.
Molecular genetics of cystinuria in French Canadians: identification of four novel mutations in type I patients.
Kidney Int
49:
1401-1406,
1996[ISI][Medline].
64.
Iiboshi, Y,
Papst PJ,
Kawasome H,
Hosoi H,
Abraham RT,
Houghton PJ,
and
Terada N.
Amino acid-dependent control of p70(s6k). Involvement of tRNA aminoacylation in the regulation.
J Biol Chem
274:
1092-1099,
1999
65.
Ishii, T,
Sato H,
Miura K,
Sagara J,
and
Bannai S.
Induction of cystine transport activity by stress.
Ann NY Acad Sci
663:
497-498,
1992[ISI][Medline].
66.
Kageyama, T,
Nakamura M,
Matsuo A,
Yamasaki Y,
Takakura Y,
Hashida M,
Kanai Y,
Naito M,
Tsuruo T,
Minato N,
and
Shimohama S.
The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier.
Brain Res
879:
115-121,
2000[ISI][Medline].
67.
Kanai, Y,
Fukasawa Y,
Cha SH,
Segawa H,
Chairoungdua A,
Kim DK,
Matsuo H,
Kim JY,
Miyamoto K,
Takeda E,
and
Endou H.
Transport properties of a system y+L neutral and basic amino acid transporter. Insights into the mechanisms of substrate recognition.
J Biol Chem
275:
20787-20793,
2000
68.
Kanai, Y,
Segawa H,
Miyamoto Ki,
Uchino H,
Takeda E,
and
Endou H.
Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98).
J Biol Chem
273:
23629-23632,
1998
69.
Kanai, Y,
Stelzner MG,
Lee WS,
Wells RG,
Brown D,
and
Hediger MA.
Expression of mRNA (D2) encoding a protein involved in amino acid transport in S3 proximal tubule.
Am J Physiol Renal Fluid Electrolyte Physiol
263:
F1087-F1092,
1992
70.
Koizumi, A,
Shoji Y,
Nozaki J,
Noguchi A,
Xiaofei E,
Dakeishi M,
Ohura T,
Tsuyoshi K,
Yasuhiko W,
Manabe M,
Takasago Y,
and
Takada G.
A cluster of lysinuric protein intolerance (LPI) patients in a northern part of Iwate, Japan due to a founder effect.
Hum Mutat
16:
270-271,
2000[Medline].
71.
Kudo, Y,
and
Boyd CA.
Heterodimeric amino acid transporters: expression of heavy but not light chains of CD98 correlates with induction of amino acid transport systems in human placental trophoblast.
J Physiol (Lond)
523:
13-18,
2000
72.
Kudo, Y,
and
Boyd CA.
The role of L-tryptophan transport in L-tryptophan degradation by indoleamine 2,3-dioxygenase in human placental explants.
J Physiol
531:
417-423,
2001
73.
Kudo, Y,
and
Boyd CA.
Characterisation of L-tryptophan transporters in human placenta: a comparison of brush border and basal membrane vesicles.
J Physiol
531:
405-416,
2001
74.
Lee, WS,
Wells RG,
Sabbag RV,
Mohandas TK,
and
Hediger MA.
Cloning and chromosomal localization of a human kidney cDNA involved in cystine, dibasic, and neutral amino acid transport.
J Clin Invest
91:
1959-1963,
1993[ISI][Medline].
75.
Lukkarinen, M,
Parto K,
Ruuskanen O,
Vainio O,
Kayhty H,
Olander RM,
and
Simell O.
B and T cell immunity in patients with lysinuric protein intolerance.
Clin Exp Immunol
116:
430-434,
1999[ISI][Medline].
76.
Lumadue, JA,
Glick AB,
and
Ruddle FH.
Cloning, sequence analysis, and expression of the large subunit of the human lymphocyte activation antigen 4F2.
Proc Natl Acad Sci USA
84:
9204-9208,
1987[Abstract].
77.
Magagnin, S,
Bertran J,
Werner A,
Markovich D,
Biber J,
Palacin M,
and
Murer H.
Poly(A)+ RNA from rabbit intestinal mucosa induces b0,+ and y+ amino acid transport activities in Xenopus laevis oocytes.
J Biol Chem
267:
15384-15390,
1992
78.
Mannion, BA,
Kolesnikova TV,
Lin SH,
Wang S,
Thompson NL,
and
Hemler ME.
The light chain of CD98 is identified as E16/TA1 protein.
J Biol Chem
273:
33127-33129,
1998
79.
Markovich, D,
Stange G,
Bertran J,
Palacin M,
Werner A,
Biber J,
and
Murer H.
Two mRNA transcripts (rBAT-1 and rBAT-2) are involved in system b0,+-related amino acid transport.
J Biol Chem
268:
1362-1367,
1993
80.
Mastroberardino, L,
Spindler B,
Pfeiffer R,
Skelly PJ,
Loffing J,
Shoemaker CB,
and
Verrey F.
Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family.
Nature
395:
288-291,
1998[ISI][Medline].
81.
McNamara, PD,
Pepe LM,
and
Segal S.
Cystine uptake by rat renal brush-border vesicles.
Biochem J
194:
443-449,
1981[ISI][Medline].
82.
Mendes Ribeiro, AC,
Brunini TM,
Yaqoob M,
Aronson JK,
Mann GE,
and
Ellory JC.
Identification of system y+L as the high-affinity transporter for L-arginine in human platelets: up-regulation of L-arginine influx in uraemia.
Pflügers Arch
438:
573-575,
1999[ISI][Medline].
83.
Miyamoto, K,
Katai K,
Tatsumi S,
Sone K,
Segawa H,
Yamamoto H,
Taketani Y,
Takada K,
Morita K,
Kanayama H,
Kagawa S,
and
Takeda E.
Mutations of the basic amino acid transporter gene associated with cystinuria.
Biochem J
310:
951-955,
1995[ISI][Medline].
84.
Miyamoto, K,
Segawa H,
Tatsumi S,
Katai K,
Yamamoto H,
Taketani Y,
Haga H,
Morita K,
and
Takeda E.
Effects of truncation of the COOH-terminal region of a Na+-independent neutral and basic amino acid transporter on amino acid transport in Xenopus oocytes.
J Biol Chem
271:
16758-16763,
1996
85.
Mora, C,
Chillaron J,
Calonge MJ,
Forgo J,
Testar X,
Nunes V,
Murer H,
Zorzano A,
and
Palacin M.
The rBAT gene is responsible for L-cystine uptake via the b0,+-like amino acid transport system in a "renal proximal tubular" cell line (OK cells).
J Biol Chem
271:
10569-10576,
1996
86.
Mosckovitz, R,
Udenfriend S,
Felix A,
Heimer E,
and
Tate SS.
Membrane topology of the rat kidney neutral and basic amino acid transporter.
FASEB J
8:
1069-1074,
1994
87.
Mosckovitz, R,
Yan N,
Heimer E,
Felix A,
Tate SS,
and
Udenfriend S.
Characterization of the rat neutral and basic amino acid transporter utilizing anti-peptide antibodies.
Proc Natl Acad Sci USA
90:
4022-4026,
1993[Abstract].
88.
Munck, LK,
Grondahl ML,
Thorboll JE,
Skadhauge E,
and
Munck BG.
Transport of neutral, cationic and anionic amino acids by systems B, b0,+, XAG, and ASC in swine small intestine.
Comp Biochem Physiol A Mol Integr Physiol
126:
527-537,
2000[ISI][Medline].
89.
Mykkänen, J,
Torrents D,
Pineda M,
Camps M,
Yoldi ME,
Horelli-Kuitunen N,
Huoponen K,
Heinonen M,
Oksanen J,
Simell O,
Savontaus ML,
Zorzano A,
Palacin M,
and
Aula P.
Functional analysis of novel mutations in y+LAT-1 amino acid transporter gene causing lysinuric protein intolerance (LPI).
Hum Mol Genet
9:
431-438,
2000
90.
Nakamura, E,
Sato M,
Yang H,
Miyagawa F,
Harasaki M,
Tomita K,
Matsuoka S,
Noma A,
Iwai K,
and
Minato N.
4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer.
J Biol Chem
274:
3009-3016,
1999
91.
Nakauchi, J,
Matsuo H,
Kim DK,
Goto A,
Chairoungdua A,
Cha SH,
Inatomi J,
Shiokawa Y,
Yamaguchi K,
Saito I,
Endou H,
and
Kanai Y.
Cloning and characterization of a human brain Na+-independent transporter for small neutral amino acids that transports D-serine with high affinity.
Neurosci Lett
287:
231-235,
2000[ISI][Medline].
92.
Nirenberg, MJ,
Tate SS,
Mosckovitz R,
Udenfriend S,
and
Pickel VM.
Immunocytochemical localization of the renal neutral and basic amino acid transporter in rat adrenal gland, brainstem, and spinal cord.
J Comp Neurol
356:
505-522,
1995[ISI][Medline].
93.
Noguchi, A,
Shoji Y,
Koizumi A,
Takahashi T,
Matsumori M,
Kayo T,
Ohata T,
Wada Y,
Yoshimura I,
Maisawa S,
Konishi M,
Takasago Y,
and
Takada G.
SLC7A7 genomic structure and novel variants in three Japanese lysinuric protein intolerance families.
Hum Mutat
15:
367-372,
2000[ISI][Medline].
94.
Novak, DA,
Matthews JC,
Beveridge MJ,
Yao SY,
Young J,
and
Kilberg MS.
Demonstration of system y+L activity on the basal plasma membrane surface of rat placenta and developmentally regulated expression of 4F2HC mRNA.
Placenta
18:
643-648,
1997[ISI][Medline].
95.
Okamoto, K,
Ohgimoto S,
Nishio M,
Tsurudome M,
Kawano M,
Komada H,
Ito M,
Sakakura Y,
and
Ito Y.
Paramyxovirus-induced syncytium cell formation is suppressed by a dominant negative fusion regulatory protein-1 (FRP-1)/CD98 mutated construct: an important role of FRP-1 in virus-induced cell fusion.
J Gen Virol
78:
775-783,
1997[Abstract].
96.
Ozegovic, B,
McNamara PD,
and
Segal S.
Cystine uptake by rat jejunal brushborder membrane vesicles.
Biosci Rep
2:
913-920,
1982[ISI][Medline].
97.
Palacin, M,
Bertran J,
and
Zorzano A.
Heteromeric amino acid transporters explain inherited aminoacidurias.
Curr Opin Nephrol Hypertens
9:
547-553,
2000[ISI][Medline].
98.
Palacin, M,
Estevez R,
Bertran J,
and
Zorzano A.
Molecular biology of mammalian plasma membrane amino acid transporters.
Physiol Rev
78:
969-1054,
1998
99.
Palacin, M,
Estevez R,
and
Zorzano A.
Cystinuria calls for heteromultimeric amino acid transporters.
Curr Opin Cell Biol
10:
455-461,
1998[ISI][Medline].
100.
Pardridge, WM.
Brain metabolism: a perspective from the blood-brain barrier.
Physiol Rev
63:
1481-1535,
1983
101.
Peter, GJ,
Davies A,
Watt PW,
Birrell J,
and
Taylor PM.
Interactions between the thiol-group reagent N-ethylmaleimide and neutral and basic amino acid transporter-related amino acid transport.
Biochem J
343:
169-176,
1999[ISI][Medline].
102.
Peter, GJ,
Panova TB,
Christie GR,
and
Taylor PM.
Cysteine residues in the C-terminus of the neutral- and basic-amino-acid transporter heavy-chain subunit contribute to functional properties of the system b0,+-type amino acid transporter.
Biochem J
351:
3677-3682,
2000.
103.
Pfeiffer, R,
Loffing J,
Rossier G,
Bauch C,
Meier C,
Eggermann T,
Loffing-Cueni D,
Kühn LC,
and
Verrey F.
Luminal heterodimeric amino acid transporter defective in cystinuria.
Mol Biol Cell
10:
4135-4147,
1999
104.
Pfeiffer, R,
Rossier G,
Spindler B,
Meier C,
Kühn L,
and
Verrey F.
Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and members of the glycoprotein-associated amino acid transporter family.
EMBO J
18:
49-57,
1999
105.
Pfeiffer, R,
Spindler B,
Loffing J,
Skelly PJ,
Shoemaker CB,
and
Verrey F.
Functional heterodimeric amino acid transporters lacking cysteine residues involved in disulfide bond.
FEBS Lett
439:
157-162,
1998[ISI][Medline].
106.
Pickel, VM,
Nirenberg MJ,
Chan J,
Mosckovitz R,
Udenfriend S,
and
Tate SS.
Ultrastructural localization of a neutral and basic amino acid transporter in rat kidney and intestine.
Proc Natl Acad Sci USA
90:
7779-7783,
1993
107.
Pickel, VM,
Pohorille A,
Chan J,
Tate SS,
and
Nirenberg MJ.
Regional and subcellular distribution of a neutral and basic amino acid transporter in forebrain neurons containing nitric oxide synthase.
J Comp Neurol
404:
459-472,
1999[ISI][Medline].
108.
Pineda, M,
Fernandez E,
Torrents D,
Estevez R,
Lopez C,
Camps M,
Lloberas J,
Zorzano A,
and
Palacin M.
Identification of a membrane protein, LAT-2, that co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids.
J Biol Chem
274:
19738-19744,
1999
109.
Pras, E,
Arber N,
Aksentijevich I,
Katz G,
Schapiro JM,
Prosen L,
Gruberg L,
Harel D,
Liberman U,
Weissenbach J,
Pras M,
and
Kastner DL.
Localization of a gene causing cystinuria to chromosome 2p.
Nat Genet
6:
415-419,
1994[ISI][Medline].
110.
Pras, E,
Golomb E,
Drake C,
Aksentijevich I,
Katz G,
and
Kastner DL.
A splicing mutation (891+4AG) in SLC3A1 leads to exon 4 skipping and causes cystinuria in a Moslem Arab family.
Hum Mutat Suppl
1:
S28-S30,
1998.
111.
Pras, E,
Raben N,
Golomb E,
Aber N,
Aksentijevich I,
Schapiro JM,
Harel D,
Katz G,
Liberman U,
Pras M,
and
Kastner DL.
Mutations in the SLC3A1 transporter gene in cystinuria.
Am J Hum Genet
56:
1297-1303,
1995[ISI][Medline].
112.
Prasad, PD,
Wang H,
Huang W,
Kekuda R,
Rajan DP,
Leibach FH,
and
Ganapathy V.
Human LAT1, a subunit of system L amino acid transporter: molecular cloning and transport function.
Biochem Biophys Res Commun
255:
283-288,
1999[ISI][Medline].
113.
Purroy, J,
Bisceglia L,
Jaeken J,
Gasparini P,
Palacin M,
and
Nunes V.
Detection of two novel large deletions in SLC3A1 by semi-quantitative fluorescent multiplex PCR.
Hum Mutat
15:
373-379,
2000[ISI][Medline].
114.
Quackenbush, E,
Clabby M,
Gottesdiener KM,
Barbosa J,
Jones NH,
Strominger JL,
Speck S,
and
Leiden JM.
Molecular cloning of complementary DNAs encoding the heavy chain of the human 4F2 cell-surface antigen: a type II membrane glycoprotein involved in normal and neoplastic cell growth.
Proc Natl Acad Sci USA
84:
6526-6530,
1987[Abstract].
115.
Rajan, DP,
Huang W,
Kekuda R,
George RL,
Wang J,
Conway SJ,
Devoe LD,
Leibach FH,
Prasad PD,
and
Ganapathy V.
Differential influence of the 4F2 heavy chain and the protein related to b0,+ amino acid transport on substrate affinity of the heteromeric b0,+ amino acid transporter.
J Biol Chem
275:
14331-14335,
2000
116.
Rajan, DP,
Kekuda R,
Huang W,
Devoe LD,
Leibach FH,
Prasad PD,
and
Ganapathy V.
Cloning and functional characterization of a Na+-independent, broad-specific neutral amino acid transporter from mammalian intestine.
Biochim Biophys Acta
1463:
6-14,
2000[ISI][Medline].
117.
Rajan, DP,
Kekuda R,
Huang W,
Wang H,
Devoe LD,
Leibach FH,
Prasad PD,
and
Ganapathy V.
Cloning and expression of a b0,+-like amino acid transporter functioning as a heterodimer with 4F2hc instead of rBAT. A new candidate gene for cystinuria.
J Biol Chem
274:
29005-29010,
1998
118.
Rajantie, J,
Simell O,
and
Perheentupa J.
Lysinuric protein intolerance. Basolateral transport defect in renal tubuli.
J Clin Invest
67:
1078-1082,
1981[ISI][Medline].
119.
Ritchie, JW,
Peter GJ,
Shi YB,
and
Taylor PM.
Thyroid hormone transport by 4F2hc-IU12 heterodimers expressed in Xenopus oocytes.
J Endocrinol
163:
R5-R9,
1999[Abstract].
120.
Rosenberg, LE,
Downing S,
Durant JL,
and
Segal S.
Cystinuria: biochemical evidence for three genetically distinct diseases.
J Clin Invest
45:
365-371,
1966[ISI][Medline].
121.
Rossier, G,
Meier C,
Bauch C,
Summa V,
Sordat B,
Verrey F,
and
Kühn LC.
LAT2, a new basolateral 4F2hc/CD98-associated amino acid transporter of kidney and intestine.
J Biol Chem
274:
34948-34954,
1999
122.
Saadi, I,
Chen XZ,
Hediger M,
Ong P,
Pereira P,
Goodyer P,
and
Rozen R.
Molecular genetics of cystinuria: mutation analysis of SLC3A1 and evidence for another gene in type I (silent) phenotype.
Kidney Int
54:
48-55,
1998[ISI][Medline].
123.
Sarkar, D,
Kambe F,
Hirata A,
Iseki A,
Ohmori S,
and
Seo H.
Expression of E16/CD98LC/hLAT1 is responsive to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
FEBS Lett
462:
430-434,
1999[ISI][Medline].
124.
Sato, H,
Kuriyama-Matsumura K,
Hashimoto T,
Sasaki H,
Wang H,
Ishii T,
Mann GE,
and
Bannai S.
Effect of oxygen on induction of the cystine transporter by bacterial lipopolysaccharide in mouse peritoneal macrophages.
J Biol Chem
276:
10407-10412,
2001
125.
Sato, H,
Kuriyama-Matsumura K,
Siow RC,
Ishii T,
Bannai S,
and
Mann GE.
Induction of cystine transport via system x
126.
Sato, H,
Tamba M,
Ishii T,
and
Bannai S.
Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins.
J Biol Chem
274:
11455-11458,
1999
127.
Schafer, JA,
and
Watkins WL.
Transport of L-cystine in isolated perfused proximal straight tubules.
Pflügers Arch
401:
143-151,
1984[ISI][Medline].
128.
Schwertfeger M, Pissowotzki K, Fleck C, and Taylor PM. Regulation
of L-leucine transport in rat kidney by dexamethasone and
tri-iodothyronine. J Physiol. In press.
129.
Segal, S,
McNamara PD,
and
Pepe LM.
Transport interaction of cystine and dibasic amino acids in renal brush border vesicles.
Science
197:
169-171,
1977[ISI][Medline].
130.
Segawa, H,
Fukasawa Y,
Miyamoto K,
Takeda E,
Endou H,
and
Kanai Y.
Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity.
J Biol Chem
274:
19745-19751,
1999
131.
Smith, DW,
Scriver CR,
Tenenhouse HS,
and
Simell O.
Lysinuric protein intolerance mutation is expressed in the plasma membrane of cultured skin fibroblasts.
Proc Natl Acad Sci USA
84:
7711-7715,
1987[Abstract].
132.
Shishido, T,
Uno S,
Kamohara M,
Tsuneoka-Suzuki T,
Hashimoto Y,
Enomoto T,
and
Masuko T.
Transformation of BALB3T3 cells caused by over-expression of rat CD98 heavy chain (HC) requires its association with light chain: mis-sense mutation in a cysteine residue of CD98HC eliminates its transforming activity.
Int J Cancer
87:
311-316,
2000[ISI][Medline].
133.
Sperandeo, MP,
Bassi MT,
Riboni M,
Parenti G,
Buoninconti A,
Manzoni M,
Incerti B,
Larocca MR,
Di Rocco M,
Strisciuglio P,
Dianzani I,
Parini R,
Candito M,
Endo F,
Ballabio A,
Andria G,
Sebastio G,
and
Borsani G.
Structure of the SLC7A7 gene and mutational analysis of patients affected by lysinuric protein intolerance.
Am J Hum Genet
66:
92-99,
2000[ISI][Medline].
134.
Spindler, B,
Mastroberardino L,
Custer M,
and
Verrey F.
Characterization of early aldosterone-induced RNAs identified in A6 kidney epithelia.
Pflügers Arch
434:
323-331,
1997[ISI][Medline].
135.
States, B,
and
Segal S.
Cystine and dibasic amino acid uptake by opossum kidney cells.
J Cell Physiol
143:
555-562,
1990[ISI][Medline].
136.
Stevens, BR,
and
Vo CB.
Membrane transport of neuronal nitric oxide synthase substrate L-arginine is constitutively expressed with CAT1 and 4F2hc, but not CAT2 or rBAT.
J Neurochem
71:
564-570,
1998[ISI][Medline].
137.
Tabata, N,
Ido M,
Suga S,
Ohgimoto S,
Tsurudome M,
Kawano M,
Nishio M,
Watanabe N,
Okamoto K,
Komada H,
Sakurai M,
and
Ito Y.
Protein tyrosine kinase activation provides an early and obligatory signal in anti-FRP-1/CD98/4F2 monoclonal antibody induced cell fusion mediated by HIV gp160.
Med Microbiol Immunol (Berl)
186:
115-123,
1997[ISI][Medline].
138.
Tate, SS,
Yan N,
and
Udenfriend S.
Expression cloning of a Na+-independent neutral amino acid transporter from rat kidney.
Proc Natl Acad Sci USA
89:
1-5,
1992[Abstract].
139.
Teixeira, S,
Di Grandi S,
and
Kühn LC.
Primary structure of the human 4F2 antigen heavy chain predicts a transmembrane protein with a cytoplasmic NH2 terminus.
J Biol Chem
262:
9574-9580,
1987
140.
Teixeira, S,
and
Kühn LC.
Post-transcriptional regulation of the transferrin receptor and 4F2 antigen heavy chain mRNA during growth activation of spleen cells.
Eur J Biochem
202:
819-826,
1991[Abstract].
141.
Thwaites, DT,
Markovich D,
Murer H,
and
Simmons NL.
Na+-independent lysine transport in human intestinal Caco-2 cells.
J Membr Biol
151:
215-224,
1996[ISI][Medline].
142.
Torrents, D,
Estevez R,
Pineda M,
Fernandez E,
Lloberas J,
Shi YB,
Zorzano A,
and
Palacin M.
Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance.
J Biol Chem
273:
32437-32445,
1998
143.
Torrents, D,
Mykkänen J,
Pineda M,
Feliubadalo L,
Estevez R,
de Cid R,
Sanjurjo P,
Zorzano A,
Nunes V,
Huoponen K,
Reinikainen A,
Simell O,
Savontaus ML,
Aula P,
and
Palacin M.
Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene.
Nat Genet
21:
293-296,
1999[ISI][Medline].
144.
Tsumura, H,
Kimura S,
Kawano M,
Tsurudome M,
Shimura K,
and
Ito Y.
Mouse alloantigen Ly10 is identical to murine fusion regulatory protein-1 (mFRP-1)/4F2/CD98: aberrant expression of mFRP-1/Ly10 allotypes in cells derived from CDF1 mice due to the gene deletion.
Cell Immunol
184:
153-160,
1998[ISI][Medline].
145.
Tsurudome, M,
Ito M,
Takebayashi S,
Okumura K,
Nishio M,
Kawano M,
Kusagawa S,
Komada H,
and
Ito Y.
Cutting edge: primary structure of the light chain of fusion regulatory protein-1/CD98/4F2 predicts a protein with multiple transmembrane domains that is almost identical to the amino acid transporter E16.
J Immunol
162:
2462-2466,
1999
146.
Vadgama, JV,
and
Christensen HN.
Discrimination of Na+-independent transport systems L, T, and asc in erythrocytes. Na+ independence of the latter a consequence of cell maturation?
J Biol Chem
260:
2912-2922,
1995[Abstract].
147.
Van Winkle, LJ.
Amino acid transport in developing animal oocytes and early conceptuses.
Biochim Biophys Acta
947:
173-208,
1988[ISI][Medline].
148.
Van Winkle, LJ,
Campione AL,
and
Gorman JM.
Na+-independent transport of basic and zwitterionic amino acids in mouse blastocysts by a shared system and by processes which distinguish between these substrates.
J Biol Chem
263:
3150-3163,
1988
149.
Verrey, F,
Jack DL,
Paulsen IT,
Saier MH, Jr,
and
Pfeiffer R.
New glycoprotein-associated amino acid transporters.
J Membr Biol
172:
181-192,
1999[ISI][Medline].
150.
Verrey, F,
Meier C,
Rossier G,
and
Kühn LC.
Glycoprotein-associated amino acid exchangers: broadening the range of transport specificity.
Pflügers Arch
440:
503-512,
2000[ISI][Medline].
151.
Volk, T,
Frömter E,
and
Korbmacher C.
Hypertonicity activates nonselective cation channels in mouse cortical collecting duct cells.
Proc Natl Acad Sci USA
92:
8478-8482,
1995[Abstract].
152.
Völkl, H,
and
Silbernagl S.
Mutual inhibition of L-cystine/L-cysteine and other neutral amino acids during tubular reabsorption. A microperfusion study in rat kidney.
Pflügers Arch
395:
190-195,
1982[ISI][Medline].
153.
Völkl, H,
and
Silbernagl S.
Reexamination of the interplay between dibasic amino acids and I-cystine/L-cysteine during tubular reabsorption.
Pflügers Arch
395:
196-200,
1982[ISI][Medline].
154.
Wagner, CA,
Bröer A,
Albers A,
Gamper N,
Lang F,
and
Bröer S.
The heterodimeric amino acid transporter 4F2hc/LAT1 is associated in Xenopus oocytes with a non-selective cation channel that is regulated by the serine/threonine kinase sgk1.
J Physiol (Lond)
526:
35-46,
2000
155.
Wang, Y,
and
Tate SS.
Oligomeric structure of a renal cystine transporter: implications in cystinuria.
FEBS Lett
368:
389-392,
1995[ISI][Medline].
156.
Weissbach, L,
Handlogten ME,
Christensen HN,
and
Kilberg MS.
Evidence for two Na+-independent neutral amino acid transport systems in primary cultures of rat hepatocytes. Time-dependent changes in activity.
J Biol Chem
257:
12006-12011,
1982
157.
Wells, RG,
and
Hediger MA.
Cloning of a rat kidney cDNA that stimulates dibasic and neutral amino acid transport and has sequence similarity to glucosidases.
Proc Natl Acad Sci USA
89:
5596-5600,
1992[Abstract].
158.
Wells, RG,
Lee WS,
Kanai Y,
Leiden JM,
and
Hediger MA.
The 4F2 antigen heavy chain induces uptake of neutral and dibasic amino acids in Xenopus oocytes.
J Biol Chem
267:
15285-15288,
1992
159.
Yan, N,
Mosckovitz R,
Udenfriend S,
and
Tate SS.
Distribution of mRNA of a Na+-independent neutral amino acid transporter cloned from rat kidney and its expression in mammalian tissues and Xenopus laevis oocytes.
Proc Natl Acad Sci USA
89:
9982-9985,
1992[Abstract].